Authors
Latest:
Next Steps in the Development of AxatilimabCorey Cutler, MD, MPH, and Hannah Choe, MD, provide future perspectives on the development of axatilimab for patients with chronic GVHD.
Latest:
CAR T and Bispecifics Take Center Stage in New Myeloma TrialsAdam D. Cohen, MD, discusses ongoing research influencing the multiple myeloma treatment landscape.
Latest:
Areas of Growth in the Management of EGFR-Mutated Lung CancerLiza C. Villaruz, MD, discusses what research in the EGFR-positive lung cancer space has recently caught the attention of experts.
Latest:
Building a Patient-Centered Ecosystem Leads to Better CareWithin the past decade, there has been a surge in terms such as value-based care, patient-centered care, shared decision-making, and more at the macro level of health care delivery in the US.
Latest:
Addressing Informative Censoring Bias in Clinical TrialsOncology trials often celebrate treatments improving progression-free survival, yet toxicity-related censoring can bias results. Emphasizing overall survival and quality of life offers clearer insights into true clinical benefit.
Latest:
Disparities in Access to CAR T-Cell Therapy for Patients With CancerLindsey S. Treviño, PhD, discusses some of the disparities that currently exist among patients with cancer.
Latest:
Repotrectinib Shows Improvement Over First-Generation TKIs in ROS1+ NSCLCFiras B. Badin, MD, discusses the improvements seen with repotrectinib compared with first-generation ROS1-targeting tyrosine kinase inhibitors for patients with advanced ROS1-positive non–small cell lung cancer.
Latest:
Exploring the Use of Orca-T for Patients With Acute and Chronic GVHDMehrdad Abedi, MD, discusses Orca-T, a high precision cell therapy, for patients with acute and chronic graft-vs-host disease.
Latest:
World Cancer Day: Next Generation Sequencing at the Forefront of Precision MedicineNext generation sequencing is at the forefront of where technology and oncology intersect to help optimize patient outcomes and expand the overall field of cancer care.
Latest:
Phase 3 HIMALAYA Trial Shows OS Benefit of Durvalumab in HCCMilind Javle, MD, discusses the phase 3 HIMALAYA study of durvalumab and tremelimumab in patients with locally advanced or metastatic hepatocellular cancer.
Latest:
Next Steps for Finding Optimal Role for Adjuvant RCC TherapyEric A. Singer, MD, MS, discusses future developments that could improve the utilization of adjuvant therapy for high-risk renal cell carcinoma.
Latest:
Incorporating Biomarker Testing in Community Cancer Clinics: A Real-World Pilot StudyAlthough there is tremendous excitement about boundaries of science stretching beyond human imagination, realizing the real-world impact of scientific advancement on the health outcomes of patients provides a reality check on how far we still must go.
Latest:
Fazal on Modalities to Lower the Risk of Acute and Chronic GVHDSalman Fazal, MD, discusses acute and chronic graft-versus-host-disease and younger match unrelated donor transplant for patients with cancer.
Latest:
Targeted Therapy With Tafasitamab Proves Effective in DLBCLHayder Saeed, MD, discusses how the mechanism of action of tafasitamab makes the therapy a potent cancer cell killer for patients with diffuse large B-cell lymphoma.
Latest:
Anti-HER2 Treatments Can Cause Pulmonary Toxicities in HER2+ Breast CancerCharles Powell, MD, MBA, discusses the questions surrounding pulmonary toxicities when using anti-HER2 monoclonal antibodies such as trastuzumab deruxtecan for patients with HER2-positive metastatic breast cancer.
Latest:
Link Between Medicaid and Rates of Biomarker Testing in NSCLCCary Gross, MD, discusses the findings from a retrospective study which revealed there to be an association between Medicaid insurance, rates of biomarker testing, and patient outcomes among patients with advanced non–small cell lung cancer.
Latest:
CAR T-Cell Therapy Access Remains Elusive, But Solutions May Be Closer Than ExpectedWidespread access to CAR T-cell therapy remains a problem, and quite a few challenges have arisen in regards to optimizing outcomes for CAR T-cell therapy in patients with hematologic malignancies and solid tumors.
Latest:
Melanoma Treatment Advances: Fianlimab and Cemiplimab Show PromiseMeredith McKean, MD, discusses a longer-term follow-up study investigating fianlimab and cemiplimab immunotherapy in advanced melanoma.
Latest:
Exploring the Benefits of Nab-Sirolimus in Advanced PEComa TreatmentIn an interview with Targeted Oncology, Jacob Stein, MD, MPH, discussed nab-sirolimus and its impact on patients with advanced PEComa.
Latest:
Implications of the EPOCH Trial in Clinical PracticeMary F. Mulcahy discusses the potential implications of the EPOCH trial in clinical practice.
Latest:
Takeaways From CheckMate-649 in Gastric/GEJ/Esophageal CancersRyan Sugarman, MD, discusses the key takeaways from the CheckMate-649 trial of patients with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma receiving nivolumab combined with chemotherapy compared with chemotherapy alone in the first-line.
Latest:
Individualized Approaches and Challenges in MyelofibrosisRaajit K. Rampal, MD, PhD, discusses how the field of gene therapy and precision medicine is evolving in the context of myelofibrosis treatment.
Latest:
Acute Lymphoblastic Leukemia in Older Adults: Is Chemotherapy-Free Treatment in the Future?Investigation of intensive chemotherapy regimens has unfortunately resulted in a lack of improvement in outcomes for patients with acute lymphoblastic leukemia in the second of the bimodal peaks.
Latest:
Case 4: Later Lines of Therapy for Patients With Recurrent HCCExpert panelists consider later-line treatment options for a patient with recurrent hepatocellular carcinoma.
Latest:
Future Directions for Treating Stage 1B, Grade 3 Endometrial CancerDavid Barrington, MD, discusses the next steps for oncologists treating patients with stage 1B, grade 3 endometrial cancer.
Latest:
Exploring Advancements in Higher-Risk MDSDespite recent setbacks in clinical trials, there is still hope for improving treatments for high-risk myelodysplastic syndromes.
Latest:
Exploring Therapies in Combination With Cytoreductive Nephrectomy in RCCKetan K. Badani, MD, discusses whether cytoreductive nephrectomies are efficacious when combined with immunotherapeutic agents in patients with renal cell carcinoma.
Latest:
Known Biomarkers, Better Care: Optimizing a CDS Tool to Guide Personalized Cancer TreatmentDaniel Rubin, PharmD, discusses key takeaways from a study exploring the use. of a clinical decision tool for biomarker documentation.
Latest:
Survival Gains and Challenges: The CROSS Trial in GEJ CancerYanghee Woo, MD, discusses the details and lasting impact of the CROSS trial in the treatment of gastroesophageal junction and esophageal cancers.
Latest:
Updated MAIA Trial Data Show Improved Survival for Multiple MyelomaNizar Bahlis, MD, discusses the findings from the randomized phase III MAIA trial, which evaluated the combination regimen of daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in transplant-ineligible patients with multiple myeloma.
